|
gptkbp:instance_of
|
gptkb:drug
|
|
gptkbp:bfsLayer
|
5
|
|
gptkbp:bfsParent
|
gptkb:Searle_Pharmaceuticals
|
|
gptkbp:approves
|
gptkb:Australia
gptkb:UK
gptkb:USA
gptkb:EU
gptkb:Native_American_tribe
|
|
gptkbp:brand
|
gptkb:Dexedrine
Pro Centra
Zenzedi
|
|
gptkbp:class
|
phenethylamine
|
|
gptkbp:commissioned
|
gptkb:1929
|
|
gptkbp:contraindication
|
gptkb:sneaker
hyperthyroidism
history of drug abuse
cardiovascular disorders
|
|
gptkbp:discovered_by
|
gptkb:Bennett_S._Cohen
|
|
gptkbp:environmental_impact
|
high
|
|
gptkbp:excretion
|
urine
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Dextroamphetamine
|
|
gptkbp:ingredients
|
C9 H13 N
|
|
gptkbp:interacts_with
|
antacids
antidepressants
MAO inhibitors
antihypertensives
|
|
gptkbp:is_atype_of
|
N06 B A02
|
|
gptkbp:is_available_on
|
gptkb:tablet
gptkb:item
extended-release capsule
immediate-release capsule
|
|
gptkbp:is_used_for
|
ADHD
narcolepsy
|
|
gptkbp:iso639-3
|
gptkb:amphetamine
|
|
gptkbp:legal_issue
|
controlled substance
|
|
gptkbp:lifespan
|
10-12 hours
|
|
gptkbp:manager
|
oral
intravenous
|
|
gptkbp:mass
|
135.21 g/mol
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:monitors
|
0 A0 D1 B1 B1 A
|
|
gptkbp:side_effect
|
anxiety
insomnia
dry mouth
increased heart rate
loss of appetite
|
|
gptkbp:tdp
|
1 F7 A
|
|
gptkbp:treatment
|
gptkb:historical_event
obesity
cognitive enhancement
|
|
gptkbp:type_of
|
51-64-9
|